-- 瑞迪博士實驗室（Dr. Reddy's Laboratories，股票代碼：RDY）週三表示，已收到加拿大衛生部的合規通知，獲准在加拿大銷售其仿製藥司美格魯肽注射。 該公司表示，此次獲得監管部門批准，使其成為加拿大首家獲準銷售該2型糖尿病治療藥物的公司。 該公司還表示，此次授權涵蓋2毫克和4毫克兩種劑量的注射筆，並且提前於衛生部的目標審查日期獲得批准。 該公司股價週三下跌1.9%。
Price: $13.77, Change: $-0.26, Percent Change: -1.89%
Related Articles
Australia
General Motors Could Top 2026 Outlook if Economy Stabilizes, UBS Says
General Motors (GM) could beat its 2026 outlook if the economy steadies, with further earnings growth likely into 2027 from cost control, electric vehicle profitability, stronger vehicle mix, and share buybacks, UBS said in a note emailed Wednesday.Investor concerns over commodity costs and demand risk misses General Motors' stronger execution, flexibility and spending control, according to the note.General Motors' outlook has some elements of conservatism because the company has not included a possible restocking of high-profit pickups and SUVs in its guidance, UBS said.The firm noted that possible USMCA trade talks are more likely to help the company than hurt it, though not included in its outlook.UBS kept its buy rating on General Motors and lowered its price target to $102 from $105.Price: $76.08, Change: $-2.87, Percent Change: -3.63%
$GM
Research
CGI Keeps Outperform Rating, C$150 Target at National Bank, Citing "Compelling Value", In-Line Q2 Results and "Light(er) Booking"
Price: $90.23, Change: $-10.41, Percent Change: -10.34%
$GIB-A.TO
Oil & Energy